Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

N-terminal pro-C-type natriuretic peptide in serum associated with bone destruction in patients with multiple myeloma.

Mylin AK, Goetze JP, Heickendorff L, Ahlberg L, Dahl IM, Abildgaard N, Gimsing P; Nordic Myeloma Study Group.

Biomark Med. 2015;9(7):679-89. doi: 10.2217/bmm.15.35.

PMID:
26174842
2.

Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma.

Mylin AK, Abildgaard N, Johansen JS, Heickendorff L, Kreiner S, Waage A, Turesson I, Gimsing P; Nordic Myeloma Study Group.

Leuk Lymphoma. 2015;56(9):2650-9. doi: 10.3109/10428194.2015.1004168. Epub 2015 Feb 11.

PMID:
25573204
3.

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.

Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H, Gruber A, Guldbrandsen N, Haukås E, Carlson K, Kvam AK, Nahi H, Lindås R, Andersen NF, Turesson I, Waage A, Westin J; Nordic Myeloma Study Group.

Blood. 2013 Jun 6;121(23):4647-54. doi: 10.1182/blood-2012-11-464503. Epub 2013 Apr 24.

4.

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.

Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group (NMSG).

Eur J Haematol. 2012 Jun;88(6):485-96. doi: 10.1111/j.1600-0609.2012.01775.x. Epub 2012 Mar 30.

5.

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.

Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, Bringhen S, Mary JY, Gimsing P, Termorshuizen F, Haznedar R, Caravita T, Moreau P, Turesson I, Musto P, Benboubker L, Schaafsma M, Sonneveld P, Facon T; Nordic Myeloma Study Group; Italian Multiple Myeloma Network; Turkish Myeloma Study Group; Hemato-Oncologie voor Volwassenen Nederland; Intergroupe Francophone du Myélome; European Myeloma Network.

Blood. 2011 Aug 4;118(5):1239-47. doi: 10.1182/blood-2011-03-341669. Epub 2011 Jun 13.

6.

Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group.

Johnsen HE, Klausen TW, Boegsted M, Lenhoff S, Gimsing P, Christiansen I, Gedde-Dahl T, Lindås R, Mellqvist UH; Nordic Myeloma Study Group.

Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):290-6. doi: 10.3816/CLML.2010.n.060.

PMID:
20709667
7.

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.

Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukås E, Hjertner O, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sørbø JH, Wisløff F, Juliusson G, Turesson I; Nordic Myeloma Study Group.

Blood. 2010 Sep 2;116(9):1405-12. doi: 10.1182/blood-2009-08-237974. Epub 2010 May 6.

8.

UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).

Bird J, Behrens J, Westin J, Turesson I, Drayson M, Beetham R, D'Sa S, Soutar R, Waage A, Gulbrandsen N, Gregersen H, Low E; Haemato-oncology Task Force of the British Committee for Standards in Haematology, UK Myeloma Forum and Nordic Myeloma Study Group.

Br J Haematol. 2009 Oct;147(1):22-42. doi: 10.1111/j.1365-2141.2009.07807.x. Epub 2009 Aug 10. No abstract available. Erratum in: Br J Haematol. 2010 Feb;148(3):491.

PMID:
19673884
10.

Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.

Lenhoff S, Hjorth M, Turesson I, Westin J, Gimsing P, Wislöff F, Ahlberg L, Carlson K, Christiansen I, Dahl IM, Forsberg K, Brinch L, Hammerström J, Johnsen HE, Knudsen LM, Linder O, Mellqvist UH, Nesthus I, Nielsen JL; Nordic Myeloma Study Group.

Haematologica. 2006 Sep;91(9):1228-33.

11.

Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.

Mylin AK, Rasmussen T, Johansen JS, Knudsen LM, Nørgaard PH, Lenhoff S, Dahl IM, Johnsen HE; Nordic Myeloma Study Group.

Eur J Haematol. 2006 Nov;77(5):416-24. Epub 2006 Aug 23.

PMID:
16930142
12.

Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group.

Lenhoff S, Hjorth M, Westin J, Brinch L, Bäckström B, Carlson K, Christiansen I, Dahl IM, Gimsing P, Hammerström J, Johnsen HE, Juliusson G, Linder O, Mellqvist UH, Nesthus I, Nielsen JL, Tangen JM, Turesson I; Nordic Myeloma Study Group.

Br J Haematol. 2006 May;133(4):389-96.

PMID:
16643445
13.

Quality assessment of autografting by probability evaluation: model estimation by clinical end-points in newly diagnosed multiple myeloma patients.

Roer O, Hammerstrøm J, Lenhoff S, Mylin AK, Knudsen LM, Rasmussen T, Johnsen HE; Nordic Myeloma Study Group.

Cytotherapy. 2006;8(1):79-88.

PMID:
16637135
14.

Guidelines on the diagnosis and management of multiple myeloma 2005.

Smith A, Wisloff F, Samson D; UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology.

Br J Haematol. 2006 Feb;132(4):410-51. No abstract available.

PMID:
16412016
15.
16.

Early response predicts thalidomide efficiency in patients with advanced multiple myeloma.

Waage A, Gimsing P, Juliusson G, Turesson I, Gulbrandsen N, Eriksson T, Hjorth M, Nielsen JL, Lenhoff S, Westin J, Wislöff F; Nordic Myeloma Study Group.

Br J Haematol. 2004 Apr;125(2):149-55.

PMID:
15059136
17.

Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences.

Gulbrandsen N, Hjermstad MJ, Wisløff F; Nordic Myeloma Study Group.

Eur J Haematol. 2004 Mar;72(3):172-80.

PMID:
14962235
18.

Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy.

Seidel C, Lenhoff S, Brabrand S, Anderson G, Standal T, Lanng-Nielsen J, Turesson I, Børset M, Waage A; Nordic Myeloma Study Group.

Br J Haematol. 2002 Dec;119(3):672-6.

PMID:
12437643
19.

Do anthracyclines have a role in the therapy of multiple myeloma?

Rödjer S, Nilsson B, Westin J; Nordic Myeloma Study Group.

Hematol J. 2000;1(6):422-6.

PMID:
11920223
20.

Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support.

Gulbrandsen N, Wisløff F, Brinch L, Carlson K, Dahl IM, Gimsing P, Hippe E, Hjorth M, Knudsen LM, Lamvik J, Lenhoff S, Løfvenberg E, Nesthus I, Nielsen JL, Turesson I, Westin J; Nordic Myeloma Study Group.

Med Oncol. 2001;18(1):65-77.

PMID:
11778972

Supplemental Content

Loading ...
Support Center